<DOC>
	<DOCNO>NCT00560963</DOCNO>
	<brief_summary>A dose finding study locally advance and/or metastatic pancreatic cancer patient</brief_summary>
	<brief_title>Treatment Patients Suffering From Progressive Pancreas Carcinoma With Everolimus ( RAD001 ) Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically confirm locally advance , irresectable pancreatic adenocarcinoma ( head , corpus , tail ) without distant metastasis 2 . Adequate bone marrow , liver renal function everolimus treatment 3 . At least one measurable lesion accord RECIST criterion previously irradiate . 4 . Patients must least 4 week since prior major surgery recover , least 2 week recover since prior minor surgery , completion radiation , completion prior systemic anticancer . 5 . Age &gt; 18 year Exclusion criterion : 1 . Women pregnant breast feeding . 2 . Documented intolerance history allergy everolimus Gemcitabine . 3 . History another malignancy within 5 year prior study entry , except curatively treat nonmelanotic skin cancer insitu cervical cancer 4 . Known symptomatic central nervous system ( CNS ) metastases leptomeningeal involvement 5 . Chronic treatment systemic steroid another immunosuppressive agent 6 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus 7 . Patients active , bleed diathesis oral antivitamin K medication ( except low dose coumarin ) . Quickvalue &lt; 50 % prothrombine time 1,5 fold high Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Advanced metastatic pancreas carcinoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>everolimus</keyword>
</DOC>